Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Cell reports - 42(2023), 1 vom: 31. Jan., Seite 111998 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tauzin, Alexandra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.02.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2023.111998 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351674853 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351674853 | ||
| 003 | DE-627 | ||
| 005 | 20231227131100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2023.111998 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM351674853 | ||
| 035 | |a (NLM)36656710 | ||
| 035 | |a (PII)S2211-1247(23)00009-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tauzin, Alexandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a B cell responses | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a CP: Immunology | |
| 650 | 4 | |a Omicron subvariants | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a humoral responses | |
| 650 | 4 | |a hybrid immunity | |
| 650 | 4 | |a neutralization | |
| 650 | 4 | |a spike glycoproteins | |
| 650 | 4 | |a third mRNA vaccine dose | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Nicolas, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Shilei |e verfasserin |4 aut | |
| 700 | 1 | |a Benlarbi, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Medjahed, Halima |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Debashree |e verfasserin |4 aut | |
| 700 | 1 | |a Dionne, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Shang Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Gendron-Lepage, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Bo, Yuxia |e verfasserin |4 aut | |
| 700 | 1 | |a Perreault, Josée |e verfasserin |4 aut | |
| 700 | 1 | |a Goyette, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Gokool, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Arlotto, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Morrisseau, Chantal |e verfasserin |4 aut | |
| 700 | 1 | |a Tremblay, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Martel-Laferrière, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a De Serres, Gaston |e verfasserin |4 aut | |
| 700 | 1 | |a Levade, Inès |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Côté, Marceline |e verfasserin |4 aut | |
| 700 | 1 | |a Bazin, Renée |e verfasserin |4 aut | |
| 700 | 1 | |a Finzi, Andrés |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 42(2023), 1 vom: 31. Jan., Seite 111998 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:1 |g day:31 |g month:01 |g pages:111998 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2023.111998 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 1 |b 31 |c 01 |h 111998 | ||